Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 11/20 | 0.53 |
| ▸ | NR1H3 | Q13133 | 11/20 | 0.53 |
| ▸ | PDE4A | P27815 | 3/20 | 0.51 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.51 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.51 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.51 |
| ▸ | YTHDC1 | Q96MU7 | 2/20 | 0.48 |
| ▸ | PDE5A | O76074 | 1/20 | 0.46 |
| ▸ | PDE1A | P54750 | 1/20 | 0.46 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.46 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.46 |
| ▸ | XDH | P47989 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3145786 | 0.90 | PDE4A (0.49) | NR1H2NR1H3PDE4APDE4BPDE4C | |
| SCHEMBL3141022 | 0.87 | NR1H2 (0.46) | NR1H2NR1H3PDE4APDE4BPDE4C | |
| SCHEMBL3146210 | 0.87 | PDE4A (0.50) | NR1H2NR1H3PDE4APDE4BPDE4C | |
| SCHEMBL3131979 | 0.84 | PDE4A (0.56) | NR1H2NR1H3PDE4APDE4BPDE4C | |
| SCHEMBL4471493 | 0.83 | NR1H3 (0.50) | NR1H2NR1H3XDHPTGS2 | |
| SCHEMBL6255831 | 0.83 | PDE4A (0.55) | PDE4APDE4BPDE4CPDE4DYTHDC1 | |
| SCHEMBL3142065 | 0.83 | PDE4A (0.55) | PDE4APDE4BPDE4CPDE4DYTHDC1 | |
| SCHEMBL3145707 | 0.83 | PDE4A (0.55) | PDE4APDE4BPDE4CPDE4DYTHDC1 | |
| SCHEMBL3131709 | 0.83 | PDE4A (0.55) | PDE4APDE4BPDE4CPDE4DYTHDC1 | |
| SCHEMBL3141104 | 0.82 | YTHDC1 (0.55) | NR1H2NR1H3PDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004236-A1 | PHOSPHODIESTERASE 4 INHIBITORS | TEHIM ASHOK | 2010-01-07 | — | — | US | claimed |
| US-20080139583-A1 | PHOSPHODIESTERASE 4 INHIBITORS | TEHIM ASHOK | 2008-06-12 | — | — | US | claimed |
| US-7332486-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORP. (US) | 2008-02-19 | — | — | US | claimed |
| US-20070093510-A1 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORP. (US) | 2007-04-26 | — | — | US | claimed |
| CN-1688580-A | 2-Trifluoromethyl-6-aminopurine derivatives as phosphodiesterase 4 inhibitors | MEMORY PHARM CORP (US) | 2005-10-26 | — | — | CN | claimed |
| EP-1529049-A2 | DERIVATIVES OF 2-TRIFLUORMETHYL-6-AMINOPURINE AS PHOSPHODIESTERASE 4 INHIBITORS | Memory Pharmaceutical Corporation (US) | 2005-05-11 | — | — | EP | claimed |
| WO-2004014913-A2 | DERIVATIVES OF 2-TRIFLUORMETHYL-6-AMINOPURINE AS PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2004-02-19 | — | — | WO | claimed |
| US-20100004236-A1 | PHOSPHODIESTERASE 4 INHIBITORS | TEHIM ASHOK | 2010-01-07 | — | — | US | disclosed |
| EP-1529049-B1 | DERIVATIVES OF 2-TRIFLUORMETHYL-6-AMINOPURINE AS PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARM CORP (US) | 2009-11-18 | — | — | EP | disclosed |
| WO-2009067607-A2 | COMBINATIONS OF PDE4 INHIBITORS AND ANTIPSYCHOTICS FOR THE TREATMENT OF PSYCHOTIC DISORDERS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2009-05-28 | — | — | WO | disclosed |
| US-20080139583-A1 | PHOSPHODIESTERASE 4 INHIBITORS | TEHIM ASHOK | 2008-06-12 | — | — | US | disclosed |
| US-7332486-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORP. (US) | 2008-02-19 | — | — | US | disclosed |
| US-20070093510-A1 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORP. (US) | 2007-04-26 | — | — | US | disclosed |
| CN-1688580-A | 2-Trifluoromethyl-6-aminopurine derivatives as phosphodiesterase 4 inhibitors | MEMORY PHARM CORP (US) | 2005-10-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093510-A1 | Phosphodiesterase 4 inhibitors | PDE4A, PDE3B, PDE3A | NR1H2 1292/4885NR1H3 1907/4885PDE4A 1/4885 |
| US-20080139583-A1 | PHOSPHODIESTERASE 4 INHIBITORS | PDE4A, PDE3B, PDE3A | NR1H2 1292/4885NR1H3 1907/4885PDE4A 1/4885 |
| US-20100004236-A1 | PHOSPHODIESTERASE 4 INHIBITORS | PDE4A, PDE3B, PDE3A | NR1H2 1292/4885NR1H3 1907/4885PDE4A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.